Danske Bank’s Adicet Bio ACET Stock Holding History

Danske Bank’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9	Hold	1	–	–	﹤0.01%	1066
2026 Q1	$7	Hold	1	–	–	﹤0.01%	1091
2025 Q4	$8	Buy	+1	New	+$11	﹤0.01%	1486

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Danske Bank's ACET Position: Q2 2026 in Review

Danske Bank held its Adicet Bio (ACET) position steady in Q2 2026 at 1 share worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

Danske Bank first reported a position in ACET in Q4 2025 and has held it in 3 quarters since. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

Danske Bank held 1 share of Adicet Bio worth $9 as of Q2 2026.
Danske Bank left its Adicet Bio share count unchanged in Q2 2026.
Adicet Bio made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1066 holding.
Danske Bank first reported a position in Adicet Bio in Q4 2025 and has held it in 3 quarters since.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.